4+

(POTENTIAL PRODUCT CANDIDATES)

(COMPANY)

ABOUT CYTEA|BIO

A UNIQUELY VERSATILE PLATFORM TO ADDRESS COMPLEX PATHOLOGIES

10+

(DEDICATED INDIVIDUALS)

3+

(MILLIONS RAISED)

6+

(YEARS OF ACADEMIC RESEARCH BEHIND THE PLATFORM)

CYTEA|BIO IS A FRENCH BIOTECHNOLOGY START-UP BASED IN MONTPELLIER DEDICATED TO THE DEVLOPMENT OF CELL THERAPY PRODUCTS FOR COMPLEX PATHOLOGIES USING ITS PATENTED PIN PLATFORM.

THE PLATFORM ENABLES TO PIN FC-BASED LIGANDS OR MABS AT THE SURFACE OF ANY POTENT EFFECTOR CELL THEREFOR PROVIDING THE OPPORTUNITY TO CREATE OF MULTIPLE THERAPEUTIC COMBINATIONS.

(POTENTIAL COMBINATIONS)

(CONCEPT)

OUR PIN PLATFORM

ANY EFFECTOR CELL HAVING A CD16 RECEPTOR ON ITS SURFACE CAN BE USED WITHIN THE PLATFORM, INCLUDING NK CELLS OR MACROPHAGES

(CD 16 RECEPTORS)

NATURAL EFFECTOR CELLS

ANY EFFECTOR CELL HAVING A CD16 RECEPTOR ON ITS SURFACE CAN BE USED WITHIN THE PLATFORM, INCLUDING NK CELLS OR MACROPHAGES

+

(PRE-ARMING)

TARGETING LIGANDS

ANY SINGLE OR MULTIPLE MONOCLONAL ANTIBODIES, OR OTHER FC-BASED LIGANDS CAN BE USED, ONCE ENGINEERED, TO PRE-ARM THE EFFECTOR CELLS BEFORE THERAPEUTIC INJECTIONS

=

(HARNESSING)

DRUG PRODUCT

THE PLATFORM BRINGS TOGETHER POTENT HUMAN CELLS AND TARGETING LIGANDS, HARNESSING NATURAL IMMUNE PROCESSES

(DEVELOPMENT)

PIPELINE

LEAD PROGRAM IN GLIOBLASTOMA

(POTENCY)

STRONG CYTOTOXICTY

PRE-CLINICAL DATA DEMONSTRATES STRONG CYTOTOXICITY AGAINST TARGETED CELLS

(PERSISTENCE)

STRONG ARMING

SUPERIOR LOADING AND PERSISTENCE OF MABS VERSUS UNMODIFIED MABS

(VERSATILITY)

MODULAR APPROACH

POSSIBILITY TO ARM THE CELLS WITH ONE OR MULTIPLE LIGANDS

(TEAM)

TEAM

EXPERIENCED SENIOR EXECUTIVES

ALAN COOKSON, PHD

Over 40 years of experience in the pharmaceutical and healthcare industry. Founder of several biotechnology start-ups.

LIONEL BRODARD

Manager with experience in start-ups and biotech (Celgene). HEC, HSG & EPFL training.

MARC CRITON, PHD, MBA

Manager with over 26 years of experience in pharmaceutical industry. IP and Business Development oriented.

BENEDICTE FAUVEL, PHD

JESSY PRESUMEY, PHD

SUPPORTED BY A WORLD CLASS INTERNATIONAL BOARD OF DIRECTORS

LAURENT ZBINDEN

Serial entrepreneur and former. CEO of multiple companies with more than 30 years experience.

JOHN D. MCMANNIS, PHD

Former Head of Manufacturing at Mesoblast (NASDAQ: MESO). Ex- Professor at UTMD Anderson Cancer Center. Led the Cell Therapy Laboratory at UTMD and designed its facility.

ANH NGUYEN, PHD

Co-founder and Chairman of MedinCell (EPA:MEDCL). Co- founder of Syntro (NASDAQ 1987) and Invitrogen (NASDAQ 1999). Invitrogen was acquired by Thermo Fisher in 2013 for $16bn.

ANDREW GALAZKA, M.D.

Former SVP Global Clinical Development at Merck KGaA with a strong track record of drug approval (Rebif, Mavenclad). Previously Head of Scientific Affairs and Investor Relations at Serono (listing NYSE).

GABRIEL BAERTSCHI

CEO of the Grünenthal Group (€ 1,4B Sales, 4’700 employees in 2019). Previously Company President of AstraZeneca Japan and Germany. Managed brands in immuno-oncology.

J.-J. DE DARDEL, PHD

Non-executive director. Formerly Ambassador to The People’s Republic of China, to Mongolia and the DPRK (2014-2019). Previously Ambassador to France and Monaco (2011-2014).

WORLD CLASS GBM CLINICAL & SCIENTIFIC ADVISORY BOARD

ROGER STUPP

Internationally renowned medical oncologist and neuro-oncologist (Northwestern University).  Best known for his contributions in the first line treatment protocol of brain tumors (the “Stupp protocol”)

MITCHEL BERGER

Director of the UCSF Brain Tumor Center, nationally recognized expert in treating brain tumors.

NICOLAS DE TRIBOLET

Former Chairman of the Department of Neurosurgery at the University of Lausanne and of Geneva

ARIEL RUIZ I ALTABA

Full Professor at UNIGE with strong expertise cancer stem cells and their role in metastatic development

ANDREW GALAZKA

Highly experienced drug developer with a strong track record of drug approvals

PIERRE MAGISTRETTI

Former professor at EPFL and dean of the Division Biological at KAUST

PLATFORM SCIENTIFIC FOUNDERS

MARTIN VILLALBA

Research director (INSERM 4). Expert in NK cells.

PIERRE MARTINEAU

Adjunct director of the IRCM. Expert in antibody engineering.

JAVIER HERNANDEZ

Researcher at INSERM – IRMB. Expert in biology of T cells and immunotolerance.

BRUNO ROBERT

Researcher at IRCM. Expert in pre-clinical validation of monoclonal antibodies.

CHRISTIAN JORGENSEN

Initiator & director of the Institute for Regenerative Medicines & Biotherapy (IRMB) at Montpellier, France.